Sattva Swarup Neelapu MD

Hematologic Oncology

Physician

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1998 - 2001
NYC Health & Hospitals/South Brooklyn HealthResidency, Internal Medicine, 1992 - 1995
Jawaharlal Institute of Postgraduate Medical Education and ResearchClass of 1992

CMS Meaningful Use Stage 1 Certification ClinicStation, UT MD Anderson Cancer Center, 2013-2015

PubMed

Journal Articles

Assessment of Radiation Doses Delivered to Organs at Risk Among Patients with Early-Stage Favorable Hodgkin Lymphoma Treated with Contemporary Radiation Therapy
Chelsea C Pinnix, Jillian R Gunther, Sarah A Milgrom, Jason Westin, Simrit Parmar, Loretta Nastoupil, Sattva Neelapu, Bouthaina S Dabaja, JAMA Network Open
Long‐Term Overall‐ and Progression‐Free Survival After Pentostatin, Cyclophosphamide and Rituximab Therapy for Indolent Non‐Hodgkin Lymphoma
Peter McLaughlin, M Alma Rodriguez, Sattva S Neelapu, Anas Younes, Lei Feng, Michelle A Fanale, Felipe Samaniego, Barbara Pro, Luis Fayad, Fredrick Hagemeister, Jorge ..., British Journal of Haematology
Management Guidelines for Paediatric Patients Receiving Chimeric Antigen Receptor T Cell Therapy
Kris M Mahadeo, Julie C Fitzgerald, Marie E Steiner, Partow Kebriaei, Katayoun Rezvani, Ira M Cheifetz, John M Slopis, Paul L Martin, Sattva S Neelapu, Agne Tarasevici..., Nature

Abstracts/Posters

Clinical and Radiological Correlates of Neurotoxicity after Standard of Care Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma
Sattva S Neelapu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Analysis of Factors Predictive of Risk of Transformation and Time to Transformation in Patients (pts) with Mantle Cell Lymphoma _ Cohort Study of 369 Patients
Sattva S Neelapu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Efficacy Proof of Concept for Allogeneic CD123 Targeting CAR T-Cells Against Primary Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Efficient Control of Tumor P...
Sattva S Neelapu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
A Phase 2, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Either Rituximab or Lenalidomide in Patients...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Hit the Ground Running: What You Need to Know About CAR T-Cell Therapy
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

ZUMA-5: Curative Potential of Axi-Cel in Follicular LymphomaJanuary 3rd, 2025
$Kite’s Yescarta® Only CAR T-cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients with Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024$
Kite’s Yescarta® Only CAR T-cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients with Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024December 9th, 2024
Research Reveals How Fructose in Diet Enhances Tumor GrowthDecember 4th, 2024

[18F]4FN PET Imaging of Innate Immunity Activation During Immunotherapy-Induced Adverse EventsUNIVERSITY OF TX MD ANDERSON CAN CTR2022–2027
Predictors Of Clinical Outcome After Therapeutic Vaccination In Follicular LymphoNational Cancer Institute2011–2012
Enhancing Antitumor Immunity With Anti-Pd-1 Antibody In Follicular Lymphoma.National Cancer Institute2010–2011
Antigen Discovery And Development Of Tumor-Specific Lymphoma ImmunotherapyNational Cancer Institute2007–2010